← Oncology Approval Tracker

FDA DECISION ·

Phyrago

dasatinib · Handa Therapeutics

FDA approvalNew or expanded indicationPhiladelphia chromosome-positive CML and ALL
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For children age 1 year or older with chronic-phase Philadelphia chromosome-positive CML or newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia with chemotherapy.

LAMPGEN ANALYSIS

Why it matters

This approval extends the Phyrago product’s established dasatinib indications to eligible pediatric leukemia patients.

What research teams should watch

Align pediatric dosing and swallowing assessment with chemotherapy coordination and molecular response monitoring.

PRIMARY RECORDS

Sources